|
PGxPredict:CLOZAPINE
The PGxPredict:CLOZAPINE test helps determine risk of clozapine-induced agranulocytosis
PGxPredict:CLOZAPINE |
| Intended Use |
The PGxPredict:CLOZAPINE test is intended for use as an adjunct to clinical information in ascertaining the risk of clozapine-induced agranulocytosis (CIA) and the risk-benefit ratio of clozapine treatment. This test assays a single nucleotide polymorphism (SNP) in HLA-DQB1 in whole blood. The use of this test does not eliminate the need for monitoring of white blood cell counts as recommended in clozapine prescribing information. |
| Phase of Development |
Marketed |
| Gene(s) |
HLA-DQB1 (major histocompatibility complex, class II, DQ beta 1) |
| Variant(s) |
Nucleotide Change: 6672G>C
Amino Acid Change: n/a |
| Method of Detection |
Bi-Directional Sequencing |
Product Ordering Information
Call or email us to order the PGxPredict:CLOZAPINE test for your patients. Sample collection kits will be delivered to you by request. Please contact us with any questions.
Toll Free Customer Service: 1-877-2-PGXHEALTH (877-274-9432)
Fax Number: 203-786-3418
Special Features
|
